Literature DB >> 14646690

Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

Umit Yasar1, Anna M Bennet, Erik Eliasson, Stefan Lundgren, Björn Wiman, Ulf De Faire, Anders Rane.   

Abstract

SUMMARY: Cytochromes P450 (CYP) 2C8 and 2C9 are polymorphic enzymes responsible for the biosynthesis of vasoactive substances from arachidonic acid including endothelium-derived hyperpolarizing factor. Inter-individual differences in the action of these substances might be important in the pathogenesis of cardiovascular diseases such as acute myocardial infarction (AMI) and hypertension. This study describes the relationship between genetic variants of CYP2C8 and CYP2C9, and morbidity in myocardial infarction in a large Swedish patient material. The study included 1172 AMI patients and 1503 control subjects (matched by age, sex and residential area) who participated in the Stockholm Heart Epidemiology Program (SHEEP). Genotyping was performed by allelic discrimination using a 5'-nuclease assay for the CYP2C8 and CYP2C9 variants. To estimate associations to AMI risks, odds ratios (OR) with 95% confidence intervals (CI) were calculated. The frequencies of CYP2C8*1, 2C8*3, 2C9*1, 2C9*2 and 2C9*3 variants in the control group were 0.91, 0.095, 0.83, 0.11 and 0.065, respectively. The risk of AMI in the female individuals carrying the *2 or *3 variant alleles of CYP2C9 and that of all individuals carrying the *3 variant of CYP2C8 was higher [OR (95% CI): 1.3 (1.0-1.9), P = 0.09; 1.5 (1.0-2.2), P = 0.06 and 1.2 (1.0-1.5), P = 0.07, respectively] compared to the groups with CYP2C8*1 and CYP2C9*1. Possession of rare genetic variants of the CYP2C8 and CYP2C9 genes in females is associated with a modest increase in risk of AMI. This might be related to genetic differences in the formation of endogenous vasoregulating eicosanoids. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646690     DOI: 10.1097/00008571-200312000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  26 in total

1.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

2.  Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.

Authors:  Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

3.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

4.  CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Craig R Lee; Kari E North; Molly S Bray; David J Couper; Gerardo Heiss; Darryl C Zeldin
Journal:  Pharmacogenet Genomics       Date:  2007-05       Impact factor: 2.089

5.  Increased risk for cerebral ischemic stroke in diabetes: genetically polymorphic CYP mediated production of neuroprotective EETs and sulfonylurea metabolism in relation with KATP channels.

Authors:  Umit Yasar; Melih O Babaoglu
Journal:  Acta Pharmacol Sin       Date:  2018-09-25       Impact factor: 6.150

Review 6.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.

Authors:  Yaoqiu Zhu; Jiang Zhou
Journal:  ACS Med Chem Lett       Date:  2012-09-09       Impact factor: 4.345

Review 8.  Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Authors:  David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Maria Laura De Marchis; Kunjan R Dave; Alfonso Bellia; Giuseppe Fogliame; Patrizia Ferroni; Giulia Donadel; Francesco Cacciatore; Pasquale Abete; Chuanhui Dong; Antonello Pileggi; Mario Roselli; Camillo Ricordi; Paolo Sbraccia; Fiorella Guadagni; Tatjana Rundek; Davide Lauro
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

9.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Authors:  Andrew T Chan; Ann G Zauber; Meier Hsu; Aurora Breazna; David J Hunter; Rebecca B Rosenstein; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

10.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.